← back to the index
RX-012 T-type calcium-channel blocker 1998

Posicor (mibefradil) — Roche’s Blood-Pressure Drug Pulled After One Year for Deadly Interactions

cardiac-arrhythmiadrug-interactionrhabdomyolysiscardiologyclinical-pharmacologyinternal-medicine1990s
Patients exposed
~200,000 U.S. patients / nearly double worldwide
Documented harm
Dangerous/fatal interactions with ≥25 drugs; statin-induced rhabdomyolysis, bradycardic shock, ≥1 documented death
On market
Jun 1997→8 Jun 1998 (~1 year)
Status
Withdrawn

Summary

When Hoffmann-La Roche pulled Posicor from the U.S. market on 8 June 1998, just under a year after the Food and Drug Administration approved it in June 1997, the company framed the move as a precaution against drug interactions; the documented record shows that the molecule's defining pharmacology — potent, mechanism-based inhibition of the liver enzyme cytochrome P450 3A4 — made it a hazard the moment it was co-prescribed with the ordinary medicines a hypertension or angina patient already took. Posicor (mibefradil), marketed as a first-in-class blocker of low-voltage T-type calcium channels, was promoted as a cleaner, more selective antihypertensive. It instead became one of the fastest major drug withdrawals of its era, undone not by a flaw in what it did to the heart but by what it did to the metabolism of dozens of unrelated drugs.

The gap between promise and harm was structural, not incidental. By slowing CYP3A4 — the enzyme that clears a large fraction of all prescription drugs — mibefradil let co-administered medicines accumulate to toxic levels. Statins such as simvastatin built up until muscle dissolved into the bloodstream (rhabdomyolysis), threatening the kidneys; antiarrhythmics, certain antihistamines, calcium-channel blockers and beta-blockers stacked into bradycardia, shock, and cardiac arrest. By the time of withdrawal more than 25 medications were known to be dangerous in combination with Posicor, and the drug was being taken by almost 200,000 Americans and nearly twice that number worldwide.

The verdict here is therefore plain at the outset. This was not a slow-burn safety signal suppressed over years, as with some withdrawals; it was a foreseeable consequence of the drug's own measured pharmacokinetics, surfacing within months of launch. A particularly damning cluster, reported in JAMA in 1998, described patients who — following the very label advice to switch off Posicor onto another agent — went into shock within twelve hours, one of whom died, because mibefradil's enzyme inhibition persisted for days after the last dose.

The reckoning was swift rather than litigious. Roche withdrew the drug globally, the FDA documented the action in the Federal Register, and the episode became a standard teaching case in clinical pharmacology: the canonical example of how a single potent CYP3A4 inhibitor can convert routine co-prescription into mass interaction risk, and how a list of contraindicated drugs that keeps growing after launch is itself the warning.

Timeline

1996
Roche files mibefradil for approval
Hoffmann-La Roche submits Posicor as a novel antihypertensive, the first selective T-type calcium-channel blocker, positioned against the established L-type agents (verapamil, diltiazem, the dihydropyridines).
1997-06
FDA approves Posicor
Mibefradil is approved for hypertension and chronic stable angina pectoris on the strength of blood-pressure and anti-anginal efficacy, with metabolism noted via CYP3A4.
1997-08
General market launch
Posicor reaches U.S. pharmacies; uptake is rapid given its 'clean' first-in-class story and once-daily dosing.
1997-12
First interaction signals
Post-marketing reports begin associating mibefradil with serious interactions involving beta-blockers, digoxin, verapamil, and diltiazem, especially in elderly patients.
1998-01
Statin rhabdomyolysis emerges
Cases of severe muscle breakdown surface in patients taking mibefradil with simvastatin and other CYP3A4-cleared statins; a later case series links 99 of 871 statin-rhabdomyolysis reports to mibefradil.
1998-Q1
Contraindication list grows
Roche and the FDA issue successive warnings; the roster of drugs dangerous with Posicor climbs past 25, including antiarrhythmics, certain antihistamines (terfenadine, astemizole), cisapride, and immunosuppressants.
1998-spring
The switching hazard surfaces
Because mibefradil's CYP3A4 inhibition outlasts the drug itself, patients told to stop Posicor and start another agent risk overlapping toxicity; a cluster of bradycardic shock is recorded.
1998-06-08
Worldwide voluntary withdrawal
Roche removes Posicor from the U.S. and global markets, citing potentially fatal drug interactions. Roughly 200,000 Americans and nearly double worldwide had been exposed in under a year.
1998-07
Profession registers the lesson
Trade and clinical outlets frame the action as among the fastest withdrawals of a recently approved drug; the FDA cites the impracticality of safely managing so many contraindications.
1998-07-22
JAMA documents the death cluster
A report describes life-threatening interactions of mibefradil and beta-blockers with dihydropyridine calcium-channel blockers, including patients in shock within 12 hours of switching and at least one death.
1998-09
Circulation publishes the post-mortem
The American Heart Association journal records the withdrawal and its rationale, cementing the case in the cardiology literature.
1998-10-08
Federal Register notice
The FDA formally records that the manufacturer voluntarily removed Posicor on 8 June 1998 owing to harmful drug interactions driven by liver-enzyme inhibition.

The Selective Promise: A First-in-Class Channel Blocker Built on a Clean Story

Posicor was engineered to occupy an empty niche. Conventional calcium-channel blockers act on L-type channels and carry familiar trade-offs — reflex tachycardia with the dihydropyridines, conduction slowing with verapamil and diltiazem. Mibefradil was the first agent to selectively block T-type, low-voltage-activated calcium channels, and Roche marketed that selectivity as a cleaner mechanism: effective once-daily blood-pressure control and anti-anginal benefit without some of the older drugs' baggage. The FDA's June 1997 approval rested on that efficacy and on a tolerable single-drug profile. What the approval did not fully reckon with was the molecule's metabolic footprint. Mibefradil was not merely metabolized by CYP3A4; it was a potent, mechanism-based inhibitor of it — destroying the enzyme's activity in a way that persisted after dosing stopped. CYP3A4 clears a large share of all prescription drugs, so a potent inhibitor of it is, in effect, a drug that changes the dose of everything else a patient is taking. For a hypertension-and-angina population — older, polypharmacy-heavy, frequently on statins, antiarrhythmics, and other cardiac drugs — that property was not a footnote. It was the central fact, hidden behind a marketing story about a clean new channel.

The Turn: When Co-Prescription Became the Mechanism of Harm

The crisis did not require a hidden trial or a suppressed signal; it required only ordinary prescribing. Within months of launch, post-marketing reports tied mibefradil to serious events when stacked with the very drugs its patients routinely took. With statins cleared by CYP3A4, plasma levels rose until skeletal muscle broke down — rhabdomyolysis severe enough to threaten the kidneys; a later analysis attributed 99 of 871 statin-rhabdomyolysis cases to mibefradil. With beta-blockers, digoxin, verapamil, and diltiazem, the combination produced dangerous bradycardia and shock, especially in the elderly. The roster of contraindicated drugs did not stabilize after launch; it grew, past 25 medicines spanning antiarrhythmics, antihistamines such as terfenadine and astemizole, cisapride, and immunosuppressants. Worst of all was a property buried in the pharmacokinetics: because mibefradil's enzyme inhibition was mechanism-based, it outlasted the drug's own clearance. Patients instructed to stop Posicor and switch to another agent could be poisoned by the overlap — and a JAMA report in July 1998 documented exactly that, describing patients in shock within twelve hours of switching, one of whom died. The drug's danger was not in steady use alone but in the act of managing it.

The Reckoning: A One-Year Withdrawal and a Standing Lesson

The end was fast and, by withdrawal standards, clean. On 8 June 1998 Roche voluntarily removed Posicor from the U.S. and world markets, less than a year after approval, citing the potential for serious and fatal interactions. The FDA's reasoning, echoed across the clinical press, was blunt: the list of dangerous co-prescriptions had grown so long, and the switching hazard was so unmanageable, that no realistic labeling could make the drug safe in the polypharmacy population it served. There was no protracted mass-tort spectacle here and no Senate hearing; the harm was acute, attributable, and pharmacologically obvious once tabulated. Circulation published the post-mortem in September 1998; the Federal Register recorded the action that October. The byword Posicor became was not, as with later cases, a symbol of corporate concealment. It became the textbook illustration of a different failure mode — approving a drug whose intrinsic property is to disable the metabolism of everything around it, and discovering only after launch that the interaction list has no floor.

Contributing Factors

01
A drug whose core property was metabolic interference
Mibefradil was a potent, mechanism-based CYP3A4 inhibitor, an enzyme that clears a large fraction of all medicines. That made altering the effective dose of co-prescribed drugs not a rare side effect but the molecule's defining behavior — a hazard inseparable from the drug itself, not a contaminant to be managed.
02
Approval that under-weighted the interaction footprint
The June 1997 clearance rested on single-agent efficacy and a 'clean' T-type-selective story. The pre-approval review did not adequately translate a known potent CYP3A4 inhibition into the predictable mass-interaction risk it implied for an older, polypharmacy-heavy cardiac population — the population the drug was made for.
03
A target population on exactly the wrong concomitant drugs
Hypertension and angina patients are disproportionately on statins, antiarrhythmics, digoxin, and other calcium-channel and beta-blocking agents — many cleared by CYP3A4. The indication and the interaction hazard overlapped almost perfectly, so routine, guideline-concordant co-prescription was the trigger.
04
Inhibition that outlasted the drug
Because the enzyme blockade was mechanism-based, it persisted for days after the last dose. This converted the safest-seeming intervention — stopping Posicor and switching — into an active danger, producing the documented shock-and-death cluster. A drug is more hazardous, not less, when its harm survives its own withdrawal.
05
A contraindication list that kept growing after launch
The roster of dangerous co-prescriptions did not converge; it climbed past 25 in months. An expanding post-market contraindication list is itself a verdict: it signals that the labeling cannot keep pace with the interaction space, and that risk management by warning has failed.

Aftermath

The material consequence was a near-total, voluntary erasure: Posicor was gone from the world market within a year of approval, its roughly 200,000 U.S. users and nearly double that abroad migrated onto other antihypertensives, and Roche absorbed the loss of a first-in-class launch. The durable ripple ran through how the field thinks about drug-drug interactions. Mibefradil became the standard cautionary example in clinical pharmacology of mechanism-based CYP3A4 inhibition and of the special danger posed by enzyme inhibition that persists after dosing stops; it sharpened regulatory and industry attention to characterizing a candidate's CYP-inhibition profile before approval rather than discovering its interaction list in post-marketing reports. It also informed later guidance on metabolism-based interaction testing and on labeling washout periods when switching off potent inhibitors. What remains is the case itself, taught year after year: a reminder that a drug's safety cannot be judged in isolation from the pharmacy of the patients who will take it. 'Posicor' endures as shorthand for the molecule that was withdrawn not for what it did alone, but for what it did to everything else in the bottle.

Lessons

  1. Judge a candidate by its interaction footprint, not just its single-agent profile: a potent inhibitor of a major clearance enzyme effectively re-doses every co-prescribed drug, so characterize that property before approval, never after launch.
  2. Match the hazard to the population that will actually take the drug: when an indication selects for polypharmacy patients on exactly the drugs your molecule interferes with, the interaction risk is not theoretical — it is the expected case.
  3. Treat a growing post-market contraindication list as a withdrawal signal, not a labeling project: if the roster of dangerous combinations keeps climbing after launch, the warnings have already lost the race; count the exposed patients accruing during every revision.
  4. Design the off-ramp before you need it: when a drug's effect outlasts its dosing, the act of stopping it can itself harm patients, so build and test the washout and switching protocol as rigorously as the indication.
  5. Respect mechanism over reassurance: a 'clean,' selective marketing story about what a drug does to its target says nothing about what it does to the body's metabolism — diagnose the second question independently of the first.

References